NASDAQ:TYME - Tyme Technologies Stock Price, Forecast & News

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Tyme Technologies Inc (NASDAQ:TYME) posted its quarterly earnings data on Monday, November, 4th. The company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.02. View Tyme Technologies' Earnings History.

Tyme Technologies is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for Tyme Technologies.

1 brokers have issued twelve-month price targets for Tyme Technologies' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Tyme Technologies' share price to reach $10.00 in the next year. This suggests a possible upside of 549.4% from the stock's current price. View Analyst Price Targets for Tyme Technologies.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.

News stories about TYME stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tyme Technologies earned a news impact score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Tyme Technologies.

Tyme Technologies saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 6,730,000 shares, a drop of 5.2% from the December 31st total of 7,100,000 shares. Based on an average daily trading volume, of 468,000 shares, the short-interest ratio is currently 14.4 days. Approximately 13.1% of the company's stock are short sold. View Tyme Technologies' Current Options Chain.

Some companies that are related to Tyme Technologies include Frequency Therapeutics (FREQ), Homology Medicines (FIXX), Omeros (OMER), Flexion Therapeutics (FLXN), TherapeuticsMD (TXMD), DiaMedica Therapeutics (DMCAF), ImmunoGen (IMGN), Vectura Group (VEGPF), Cara Therapeutics (CARA), Urogen Pharma (URGN), AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF), Crinetics Pharmaceuticals (CRNX) and Magenta Therapeutics (MGTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Bausch Health Companies (BHC), Karyopharm Therapeutics (KPTI), OpGen (OPGN), Rigel Pharmaceuticals (RIGL), Aurora Cannabis (ACB), New Age Beverages (NBEV), AcelRx Pharmaceuticals (ACRX), Novavax (NVAX), Ovid Therapeutics (OVID) and Viking Therapeutics (VKTX).

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TYME stock can currently be purchased for approximately $1.54.

Tyme Technologies has a market capitalization of $172.40 million. The company earns $-32,980,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.View Additional Information About Tyme Technologies.

The official website for Tyme Technologies is http://www.tymeinc.com/.

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]